Menu
No results found.
Weekly Share Price & Valuation Overview
Contec Medical Systems Co.,Ltd
Contec Medical Systems Co.,Ltd engages in the research and development, production, and sale of medical diagnosis and monitoring equipment. The company's products include electronic sphygmomanometers, ambulatory blood pressure monitors, pulse oximeters, patient monitors, stethoscopes, simulators, multi-parameter vital signs monitors, central monitoring systems, electrocardiograph products, endoscopes, pocket fetal dopplers, fetal monitors, ultrasound diagnostic systems, analyzers, infusion pumps, digital brain electric activity mapping and EMG/EP systems, nebulizers, spirometers, oxygen concentrators, capnographs, and airway pressure devices. It also offers infusion and syringe pumps, massagers, sleep and snoring aids, and thermometers; and telemedicine and veterinary products, dispensing appliances, electronic colposcope, and accessories. The company sells its products through distributors in China and internationally. In addition, the company engages in the import and export, trade, related consulting, and customer service of medical equipment; marketing activities; technical development, production, and sale of molds; and production and sale of bio-based materials and dental products. The company was founded in 1996 and is headquartered in Qinhuangdao, China.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 6.70B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 7.07B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 485.56M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 139.32M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY -52.69M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 1.16
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.17
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 1.47%
- Shares Outstanding
- 401.80M
- Float Shares
- 185.54M
- Implied Shares Outstanding
- 401.80M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
8.06%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
-10.85%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
28.69%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-14.24%
- ROA Return on assets: net income ÷ total assets.
-
-1.75%
- ROE Return on equity: net income ÷ shareholder equity.
-
-3.73%
- Revenue Growth Year-over-year revenue growth.
-
-6.10%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-87.80%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
2.78%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 5.87
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.51
- Total Cash Cash and equivalents.
- CNY 1.38B
- Total Debt Short + long-term interest-bearing debt.
- CNY 906.90M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- CNY -473.32M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- -17.21
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY 74.37M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY -552.70M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
15.32%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-113.83%
- Cash Conversion (OpCF/EBITDA)
- -1.41
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.